Mifepristone or inhibition of 11β-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Δ(9)-tetrahydrocannabinol in mice

Neuroscience Letters

Volumn 341, Issue 2, 2003, Pages 164-166

  Pryce, Gareth ^a   Giovannoni, Gavin ^a   Baker, David ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

11 hydroxylase; Cannabinoids; Hypothermia; Mifepristone

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; ENZYME INHIBITOR; METYRAPONE; MIFEPRISTONE; STEROID 11BETA MONOOXYGENASE; ANALGESIC AGENT; CANNABINOID RECEPTOR; DRUG RECEPTOR; HORMONE ANTAGONIST; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CATALEPSY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPOTHERMIA; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEDATION; ANIMAL; COMPARATIVE STUDY; CONSCIOUS SEDATION; DRUG EFFECT; DRUG POTENTIATION; THERMOREGULATION; TIME;

ANALGESICS, NON-NARCOTIC; ANIMALS; BODY TEMPERATURE REGULATION; CONSCIOUS SEDATION; DRUG SYNERGISM; ENZYME INHIBITORS; HORMONE ANTAGONISTS; MALE; METYRAPONE; MICE; MIFEPRISTONE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 0037402295     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00159-9     Document Type: Article

References (10)

1. Baker D., Hankey D., Pryce G. Cannabinoid-mediated treatment of autoimmune disease of the CNS and eye. J. Neuroimmunol. 118:2001;55.
2. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
3. Brooks J.W., Pryce G., Bisogno T., Jaggar S.I., Hankey D.J., Brown P., Bridges D., Ledent C., Bifulco M., Rice A.S., Di Marzo V., Baker D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. 439:2002;83-92.
4. Mendelson J.H., Mello N.K. Effects of marijuana on neuroendocrine hormones in human males and females. NIDA Res. Monogr. 44:1984;97-114.
5. Miller P.M., Plant M. Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom. Br. Med. J. 313:(7054):1996;394-397.
6. Murphy L.L., Muñoz R.M., Adrian B.A., Villanúa M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol. Dis. 5:1998;432-446.
7. Science and Technology Committee, Ninth Report, House of Lords, (1998), http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ ldsctech/151/15101.htm.
8. Rawls S.M., Cowan A., Tallarida R.J., Geller E.B., Adler M.W. N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H- pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia. J. Pharmacol. Exp. Ther. 303:2002;395-402.
9. Tarcic N., Ovadia H., Weiss D.W., Weidenfeld J. Restraint stress-induced thymic involution and cell apoptosis are dependent on endogenous glucocorticoids. J. Neuroimmunol. 82:1998;40-46.
10. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 28:1994;209-214.